Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $34 from $32 and keeps a Buy rating on the shares. The firm sees meaningful potential upside for the shares with two near-term FDA action dates for Travere. Citi upped the company’s estimates to reflect continued demand growth for Filspari in immunoglobulin A nephropathy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics
- Travere Therapeutics Earnings Call Highlights FILSPARI Success
- Travere Therapeutics price target raised to $31 from $30 at Scotiabank
- Travere Therapeutics price target raised to $32 from $30 at Wedbush
- Travere Therapeutics Reports Strong Q2 2025 Growth